Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Humanitarian Trial Data Will Be Supplementary Reference to Confirmatory Studies: Govt
October 5, 2015
- Chuikyo Approves Draft Framework for Patient-Initiated Mixed Care; Will Establish Evaluation Council by Next Spring
October 2, 2015
- PAFSC Committee Approves Resumed Shipments of Kaketsuken’s Venilon due to Potential Shortage of Substitutes
October 2, 2015
- Drug Pricing Organization to Price JCR’s Cell Therapy Temcell
October 1, 2015
- JPWA Calls for Fair Sharing of Distribution Costs for Premium-Granted Products
October 1, 2015
- Chuikyo Debate Heats Up on Number of Generic Brands, Makers; JGA Floats New 3 Price-Band Rule
October 1, 2015
- Generic Drug Prices in Japan “Not Necessarily High” Compared to Other Countries: Pres. Yoshida of JGA
October 1, 2015
- 2 Firms Mulling Confidentiality Accords to In-License 1st Drug Seed via AMED
September 30, 2015
- Editor’s Pick: Five Healthcare News Headlines for September 14 - September 27
September 29, 2015
- MHLW Gives Greenlight to AbbVie’s Hep C Drug, Other Products
September 29, 2015
- Health Policy Bureau Chief Futagawa Tapped for MHLW’s Top Bureaucratic Post
September 28, 2015
- PMDA Reviewing Daklinza, Sunvepra for Risk of Interstitial Pneumonia
September 28, 2015
- MHLW OKs New Indications for Xarelto, Lamictal, Other Products
September 25, 2015
- Drug Pricing Tomorrow: Full Interview with MOF Budget Examiner Unami
September 25, 2015
- One-Month Lag in Regulatory Filing Accepted for Sakigake Designation
September 24, 2015
- Pharmaceutical Affairs Council Approves Basic Plan for “Humanitarian Trials”
September 24, 2015
- Panel OKs Revised Japanese Pharmacopoeia, 76 Products Newly Included
September 18, 2015
- MHLW to Continue to Suspend HPV Vaccine Recommendation
September 18, 2015
- 51 Products Officially Filed for Sakigake Designation after MHLW Screening
September 18, 2015
- Add Myasthenia Gravis, Myositis to Opdivo Label: MHLW
September 17, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…